Aspirin And Extended-release Dipyridamole Capsule, Extended Release
NDC Package 42571-274-60
Package Information
Aspirin And Extended-release Dipyridamole capsules is aspirin and extended-release dipyridamole capsule is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. This formulation utilizes a capsule, extended release delivery system. Marketed by Micro Labs Limited, this product is identified by NDC 42571-274 and is authorized under FDA application ANDA209929.
Identification & Billing
- RxCUI: 259081 - aspirin 25 MG / dipyridamole 200 MG 12HR Extended Release Oral Capsule
- RxCUI: 259081 - 12 HR aspirin 25 MG / dipyridamole 200 MG Extended Release Oral Capsule
- RxCUI: 259081 - 12 HR ASA 25 MG / Dipyridamole 200 MG Extended Release Oral Capsule
Clinical Specifications
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 42571 - Micro Labs Limited
- 42571-274 - Aspirin And Extended-release Dipyridamole
- 42571-274-60 - 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
- 42571-274 - Aspirin And Extended-release Dipyridamole
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42571-274-60 identifies a specific commercial package of 60 capsule, extended release in 1 bottle of Aspirin And Extended-release Dipyridamole, a human prescription drug labeled by Micro Labs Limited. This capsule, extended release is formulated for oral use and contains aspirin; dipyridamole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Micro Labs Limited on August 16, 2021. The current certification is valid through December 31, 2026.
How is this Micro Labs Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42571027460. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.